Listar por autor "Pérez-Ruiz, Elisabeth"
Mostrando ítems 1-6 de 6
-
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Oliver, Javier; Onieva Zafra, Juan Luis; Garrido-Barros, María; Berciano-Guerrero, Miguel Ángel; Sánchez-Muñoz, Alfonso
; Lozano, María José; Farngren, Angela; Álvarez-Pérez, Martina; Martínez-Gálvez, Beatriz; Pérez-Ruiz, Elisabeth; Alba-Conejo, Emilio; Cobo Dols, Manuel Ángel; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (MDPI, 2022)
Cutaneous melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint ... -
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Sánchez-Muñoz, Alfonso; Mendiola, César; Pérez-Ruiz, Elisabeth; Rodríguez-Sánchez, César A.; Jurado, José Miguel; Alonso-Carrión, Lorenzo Javier; Ghanem, Ismael; Velasco, Guillermo de; Quero-Blanco, Cristina; Alba-Conejo, Emilio[et al.] (KARGER, 2010-11)
Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ... -
Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures
Omotesho, Quadri Ajibola; Escamilla-Sánchez, Alejandro; Pérez-Ruiz, Elisabeth; Frecha, Cecilia; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (Frontiers Research Foundation, 2024-01-25)
Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates found in sites of chronic inflammation such as tumors and autoimmune diseases. The discovery that TLS formation at tumor sites correlated with good patient ... -
Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.
Oliver, Javier; Onieva Zafra, Juan Luis; Garrido-Barros, María; Cobo Dols, Manuel Ángel; Martínez-Gálvez, Beatriz; García-Pelícano, Ana Isabel; Dubbelman-Vizcaíno, Jaime; Benítez, Jose Carlos; Zafra-Martín, Juan; Cantero-González, Alejandra; Pérez-Ruiz, Elisabeth; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (MDPI, 2023-06-26)
The present study aimed to investigate the potential of basal cell-free fluorometric DNA (cfDNA) quantification as a prognostic biomarker in advanced non-small cell lung cancer (NSCLC) patients treated with an Immune ... -
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva Zafra, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro Pereda, María del Pilar; Garrido-Aranda, Alicia; Gallego-Domínguez, Elena María; Sojo, Belén; Gálvez Carvajal, Laura; Chica Parrado, María del Rosario; Prieto Cuadra, Juan Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez-Pérez, Martína; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo Dols, Manuel Ángel; Alba-Conejo, Emilio; Barragán, Isabel[et al.] (MDPI, 2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. ... -
Precision immunotherapy in metastatic Non-Small Cell Lung Cancer patients treated with Immune Checkpoint Blockade Therapy
(UMA Editorial, 2024-04)La terapia de bloqueo de puntos de control inmunitario (ICB, por sus siglas en inglés) ha mejorado drásticamente la supervivencia en pacientes con cáncer de pulmón no microcítico metastásico (mNSCLC). Sin embargo, solo ...